Only by popularizing the law and knowing the law can the wildlife protection law be operated in compliance with the law.
Release time:
2023-03-14
On the morning of March 7, Jinhua Natural Resources and Planning Bureau, together with the Forest Police Detachment of the Municipal Public Security Bureau, the Administrative Law Enforcement Team of the Municipal Agriculture and Rural Bureau, and the Circulation Management Office of the Municipal Market Supervision Bureau, visited Jinhua Pharmaceutical Company to understand the operation of wild animal and plant products and interpret the relevant amendments to the new version of the Wildlife Protection Law. The business scope of
pharmaceutical company covers the management of wild animal products. Xie Chungang, head of the wildlife protection and management station of the Municipal Bureau of Information and Resources Planning, and his party went to the traditional Chinese medicine warehouse of the pharmaceutical company to check the purchase source of wild animal products in stock, the legal qualification of the manufacturer, the storage environment of the warehouse, and the sales process of wild animal products, and held discussions and exchanges with the management team of the pharmaceutical company, the quality control department, the department, the department of traditional Chinese medicine and other relevant personnel.
Xie Chungang said that the purpose of the inspection team's visit is to understand the operation of wildlife products of pharmaceutical companies, discuss with relevant personnel of pharmaceutical companies, and interpret the relevant amendments to the new version of the Wildlife Protection Law. Based on the on-site inspection, he put forward relevant requirements for pharmaceutical companies: the sale, purchase, or use of national key protected wild animals and their products shall be approved by the wildlife protection department of the people's government of the province, autonomous region, or municipality directly under the Central Government, and shall be obtained in accordance with the regulations. Use special signs to ensure traceability and provide legal source certificates; wild animals and their products are traded and used as medicines, it should also comply with the provisions of the the People's Republic of China and Drug Administration Law and other relevant laws and regulations. The relevant person in charge of the Forest Police Detachment of the Municipal Public Security Bureau and the Administrative Law Enforcement Team of the Municipal Agriculture and Rural Bureau also said that the relevant departments of the municipal government have been committed to how to better serve the enterprise. As long as the enterprise needs it, they can continue to provide relevant laws and regulations for the enterprise in the future. Guidance and training will also fully support and help enterprises in the management of wild animal and plant products. Wu Weisheng, general manager of
pharmaceutical company, introduced the development history and current operation of the enterprise, and had in-depth communication with the inspection team on the operation of wild animal products. He said that the inspection and law popularization of relevant departments, as well as the business support of competent departments, It has played a very important role in the future operation of pharmaceutical companies to know the law, operate in compliance with regulations and avoid risks. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page